ŠMARDOVÁ, Jana, Květoslava LIŠKOVÁ, Barbora RAVČUKOVÁ, Jitka MALČÍKOVÁ, Jitka HAUSNEROVÁ, Miluše SVITÁKOVÁ, Renata HRABÁLKOVÁ, Lenka ZLÁMALÍKOVÁ, Kateřina STAŇO KOZUBÍK, Ivona BLAHÁKOVÁ, Jana ŠPELDOVÁ, Jiří JARKOVSKÝ and Jan ŠMARDA. Complex analysis of the p53 tumor suppressor in lung carcinoma. Oncology Reports. National Hellenic Research Foundation, vol. 35, No 3, p. 1859-1867. ISSN 1021-335X. doi:10.3892/or.2015.4533. 2016.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Complex analysis of the p53 tumor suppressor in lung carcinoma
Name in Czech Komplexní analýza nádorového supresoru p53 u plicního karcinomu
Authors ŠMARDOVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Květoslava LIŠKOVÁ (203 Czech Republic), Barbora RAVČUKOVÁ (203 Czech Republic), Jitka MALČÍKOVÁ (203 Czech Republic, belonging to the institution), Jitka HAUSNEROVÁ (203 Czech Republic), Miluše SVITÁKOVÁ (203 Czech Republic), Renata HRABÁLKOVÁ (203 Czech Republic), Lenka ZLÁMALÍKOVÁ (203 Czech Republic), Kateřina STAŇO KOZUBÍK (203 Czech Republic, belonging to the institution), Ivona BLAHÁKOVÁ (203 Czech Republic, belonging to the institution), Jana ŠPELDOVÁ (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution) and Jan ŠMARDA (203 Czech Republic, belonging to the institution).
Edition Oncology Reports, National Hellenic Research Foundation, 2016, 1021-335X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10601 Cell biology
Country of publisher Greece
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.662
RIV identification code RIV/00216224:14310/16:00089204
Organization unit Faculty of Science
Doi http://dx.doi.org/10.3892/or.2015.4533
UT WoS 000368228900075
Keywords (in Czech) plicní adenokarcinom; nádorový supresor p53; FASAY; FISH; mutace TP53
Keywords in English lung adenocarcinoma; p53 tumor suppressor; FASAY; FISH; TP53 mutation
Tags AKR, EL OK, podil
Tags International impact, Reviewed
Changed by Changed by: prof. RNDr. Jan Šmarda, CSc., učo 1223. Changed: 19/2/2018 11:26.
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide. Mutations of the TP53 gene occur very frequently in lung carcinomas and they play an important role in both oncogenic transformation of lung epithelial cells and lung carcinoma progression. We determined the TP53 status in 42 samples of squamous cell lung carcinoma (SQCC) and 56 samples of lung adenocarcinoma (AC) by the functional analysis FASAY and its variant called split assay. Altogether, we detected 64 TP53 mutations in 63 patients and analyzed them by cDNA and gDNA sequencing. The TP53 mutations were found in 76.2% (32/42) of SQCC cases, and 55.4% (31/56) of ACs. Immunoblotting revealed the p53 protein accumulation in 18 samples (42.9%) among SQCC cases and 19 samples (33.9%) among AC cases. Using fluorescence in situ hybridization we detected loss of the TP53-specific 17p13.3 locus in 23 from 41 analyzed SQCC samples (56.1%) and in 20 from 54 analyzed AC samples (37.0%). We did not find any statistically significant differences in overall and disease-free survival in relation to TP53 status.
PrintDisplayed: 19/4/2024 03:40